These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 24683046)

  • 21. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
    Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke MJ; Weingart O; Kluge S; Piper M; Napoli M; Rades D; Steensma D; Djulbegovic B; Fey MF; Ray-Coquard I; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
    Cochrane Database Syst Rev; 2009 Jul; 2009(3):CD007303. PubMed ID: 19588423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.
    Coronado Daza J; Martí-Carvajal AJ; Ariza García A; Rodelo Ceballos J; Yomayusa González N; Páez-Canro C; Loza Munárriz C; Urrútia G
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011122. PubMed ID: 26671531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE.
    Roger SD; Jassal SV; Woodward MC; Soroka S; McMahon LP
    Int Urol Nephrol; 2014 Feb; 46(2):469-75. PubMed ID: 23982766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
    Ross SD; Allen IE; Henry DH; Seaman C; Sercus B; Goodnough LT
    Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
    Piotr B; Mariusz S; Jacek R
    Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis.
    Martí-Carvajal AJ; Agreda-Pérez LH; Solà I; Simancas-Racines D
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD000332. PubMed ID: 23450527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
    Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
    Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
    Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH
    Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dietary interventions for adults with chronic kidney disease.
    Palmer SC; Maggo JK; Campbell KL; Craig JC; Johnson DW; Sutanto B; Ruospo M; Tong A; Strippoli GF
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011998. PubMed ID: 28434208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
    Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosing regimen and tolerability of methoxy polyethylene glycol-epoetin beta in Chinese dialysis patients.
    Choy BY; Lam MF; Yip T; Tang HL; Wong PN; Chow CC; Yap DY; Chan TM
    Nephrology (Carlton); 2013 Aug; 18(8):533-8. PubMed ID: 23714233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.